Anlon Healthcare Limited has filed draft papers with the market regulator SEBI for the third time in order to raise funds through an Initial Public Offering.
The company already submitted its draft papers with SEBI for the first time in October 2024, but SEBI returned the draft papers in December 2024. For the second time, the company again submitted its document to SEBI on February 20, 2025, but withdrew the draft papers from the SEBI on March 28, due to unstable and volatile market conditions. However, this is the third time the company has submitted its DRHP to SEBI to launch its IPO with keeping the offer size unchanged.
This IPO consists only of a fresh issue of ₹1.4 cr equity shares. This IPO does not have an OFS process.
Funds Deployment
From this IPO, healthcare decided to utilize funds for the expansion of the manufacturing facility. Some funds will be allocated to working capital requirements, to repay the debt, and for general purposes.
About the Anlon healthcare
Anlon Healthcare Ltd is one of the leading companies in terms of research and development, also a focused chemical manufacturing company specializing in the production of high-purity advanced pharmaceutical intermediates, and active pharmaceutical ingredients like tablets, capsules, ointment, syrup, etc, ingredients in nutraceuticals formulations, pe₹onal care products and animal health products.
Financially, this company has raised profits from ₹5.82 crore to ₹9.65 crore; conversely, revenue has sharply declined from ₹112.9 crore to ₹66.6 crore at the same time.
The hired merchant banker to handle the public issue is Interactive Financial Services.
Anlon Healthcare IPO Prospectus:
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | To be Updated Soon |
Anlon Healthcare Company Financial Report
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax |
| 2022 | ₹57.54 | ₹57.64 | ₹0.11 |
| 2023 | ₹113.12 | ₹106.13 | ₹5.82 |
| 2024 | ₹66.69 | ₹56.94 | ₹9.66 |
| June 2024 | ₹37.89 | ₹32.44 | ₹4.54 |
Anlon Healthcare IPO Valuation – FY2024
Anlon Healthcare IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| Earning Per Share (EPS): | ₹6.68 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 45.92% |
| Net Asset Value (NAV): | ₹13.14 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Kronox Lab Sciences Limited | 5.81 | 31.09 | 32.51 | 17.87 | 91.44 Cr. |
| AMI Organics Limited | 11.91 | 128.22 | 6.47 | 183.05 | 701.37 Cr. |
| Supriya Lifescience Limited | 14.80 | 42.75 | 14.61 | 101.31 | 581.01 Cr. |
Objects of the Issue
- Funding capital expenditure requirements for expansion of our Manufacturing Facility (“Proposed Expansion”);
- Full or part repayment and/or prepayment of certain outstanding secured borrowings availed by our Company;
- Funding the working capital requirements of our Company; and
- Unidentified inorganic acquisitions and general corporate purposes.
IPO Lead Managers aka Merchant Bankers
- Interactive Financial Services Limited
